scholarly journals Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism

2020 ◽  
Vol Volume 13 ◽  
pp. 603-613 ◽  
Author(s):  
Zi-Zheng Song ◽  
Li-Fen Zhao ◽  
Jing Zuo ◽  
Zhi-Song Fan ◽  
Long Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Gene Polymorphism ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Standard Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Em Gene

P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?

Lung Cancer ◽  
2005 ◽  
Vol 49 ◽  
pp. S368 ◽  
Author(s):  
G. Clark ◽  
P. Cagnoni ◽  
M. Ptaszynski ◽  
M. Hamilton ◽  
P. Santabárbara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib

2021 ◽  
pp. 030089162110478
Author(s):  
Gianluca Taronna ◽  
Alessandro Leonetti ◽  
Filippo Gustavo Dall’Olio ◽  
Alessandro Rizzo ◽  
Claudia Parisi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Clinical Variable ◽  
Small Cell Lung ◽  
Significant Difference ◽  
Egfr Mutated

Introduction: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved as first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC). Some osimertinib-related interstitial lung diseases (ILDs) were shown to be transient, called transient asymptomatic pulmonary opacities (TAPO)—clinically benign pulmonary opacities that resolve despite continued osimertinib treatment—and are not associated with the clinical manifestations of typical TKI-associated ILDs. Methods: In this multicentric study, we retrospectively analyzed 92 patients with EGFR-mutated NSCLC treated with osimertinib. Computed tomography (CT) examinations were reviewed by two radiologists and TAPO were classified according to radiologic pattern. We also analyzed associations between TAPO and patients’ clinical variables and compared clinical outcomes (time to treatment failure and overall survival) for TAPO-positive and TAPO-negative groups. Results: TAPO were found in 18/92 patients (19.6%), with a median follow-up of 114 weeks. Median onset time was 16 weeks (range 6–80) and median duration time 14 weeks (range 8–37). The most common radiologic pattern was focal ground-glass opacity (54.5%). We did not find any individual clinical variable significantly associated with the onset of TAPO or significant difference in clinical outcomes between TAPO-positive and TAPO-negative groups. Conclusions: TAPO are benign pulmonary findings observed in patients treated with osimertinib. TAPO variability in terms of CT features can hinder the differential diagnosis with either osimertinib-related mild ILD or tumor progression. However, because TAPO are asymptomatic, it could be reasonable to continue therapy and verify the resolution of the CT findings at follow-up in selected cases.

The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer

Lung Cancer ◽  
2019 ◽  
Vol 128 ◽  
pp. 113-119 ◽  
Author(s):  
Kentaro Ito ◽  
Satoru Miura ◽  
Tadashi Sakaguchi ◽  
Kenta Murotani ◽  
Nobuyuki Horita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Surrogate Endpoints ◽  
Small Cell Lung ◽  
The Impact

scholarly journals Clinical outcomes for EGFR-mutant adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)

2017 ◽  
Vol 28 ◽  
pp. v540-v541 ◽  
Author(s):  
N. Marcoux ◽  
Z. Piotrowska ◽  
A.F. Farago ◽  
A.N. Hata ◽  
M.J. Mooradian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutant

scholarly journals Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?

2017 ◽  
Vol 28 (1) ◽  
pp. 185 ◽  
Author(s):  
C. Dickhoff ◽  
K.J. Hartemink ◽  
J. Kooij ◽  
P.M. van de Ven ◽  
M.A. Paul ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Trimodality Therapy

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era

Lung Cancer ◽  
2012 ◽  
Vol 76 (3) ◽  
pp. 387-392 ◽  
Author(s):  
Jin Hyun Park ◽  
Yu Jung Kim ◽  
Jeong-Ok Lee ◽  
Keun-Wook Lee ◽  
Jee Hyun Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Leptomeningeal Metastasis ◽  
Small Cell ◽  
Small Cell Lung

Indolence versus aggression in non-small cell lung cancer: defining heterogeneity to impact clinical outcomes

2016 ◽  
Vol 5 (S7) ◽  
pp. S1315-S1319
Author(s):  
Brandon S. Grimes ◽  
Kostyantyn Krysan ◽  
Linh M. Tran ◽  
Stacy J. Park ◽  
Denise R. Aberle ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer

2020 ◽  
Vol 9 (4) ◽  
pp. 1149-1158
Author(s):  
Chao Zhao ◽  
Tao Jiang ◽  
Jiayu Li ◽  
Yan Wang ◽  
Chunxia Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Exon 19 Deletion ◽  
The Impact ◽  
Exon 19
Sign in / Sign up

Export Citation Format

Share Document